48.36
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTGX Giù?
Forum
Previsione
Precedente Chiudi:
$48.88
Aprire:
$47.92
Volume 24 ore:
1.21M
Relative Volume:
1.41
Capitalizzazione di mercato:
$3.03B
Reddito:
$45.48M
Utile/perdita netta:
$169.95M
Rapporto P/E:
18.46
EPS:
2.62
Flusso di cassa netto:
$230.85M
1 W Prestazione:
-7.94%
1M Prestazione:
+28.65%
6M Prestazione:
+7.47%
1 anno Prestazione:
+67.16%
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Nome
Protagonist Therapeutics Inc
Settore
Industria
Telefono
(510) 474-0170
Indirizzo
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Confronta PTGX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
PTGX
Protagonist Therapeutics Inc
|
48.36 | 3.03B | 45.48M | 169.95M | 230.85M | 2.62 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
2024-12-06 | Iniziato | Goldman | Neutral |
2024-11-05 | Iniziato | Wedbush | Outperform |
2024-09-24 | Iniziato | TD Cowen | Buy |
2024-09-09 | Iniziato | Truist | Buy |
2023-10-30 | Iniziato | CapitalOne | Overweight |
2023-05-25 | Ripresa | Jefferies | Buy |
2022-08-25 | Iniziato | JMP Securities | Mkt Outperform |
2022-02-11 | Iniziato | BTIG Research | Buy |
2021-10-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
2021-10-11 | Aggiornamento | Northland Capital | Market Perform → Outperform |
2021-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
2021-05-24 | Iniziato | JMP Securities | Mkt Outperform |
2021-05-24 | Iniziato | Northland Capital | Outperform |
2021-01-06 | Iniziato | JP Morgan | Overweight |
2020-12-16 | Iniziato | Piper Sandler | Overweight |
2020-09-18 | Reiterato | H.C. Wainwright | Buy |
2020-07-15 | Iniziato | Jefferies | Buy |
2020-05-18 | Reiterato | H.C. Wainwright | Buy |
2019-07-08 | Iniziato | H.C. Wainwright | Buy |
2019-05-09 | Aggiornamento | Stifel | Hold → Buy |
2018-12-06 | Iniziato | Nomura | Buy |
2018-01-29 | Iniziato | Stifel | Buy |
2017-07-21 | Iniziato | BTIG Research | Buy |
Mostra tutto
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? - Yahoo Finance
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025 - Bluefield Daily Telegraph
Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday - MSN
Insider Sell: William Waddill Sells 4,000 Shares of Protagonist Therapeutics Inc (PTGX) - GuruFocus
Protagonist Therapeutics Takeda To Lead Regulatory Strategy For Rusfertide In Polycythemia Vera NDA - MarketScreener
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. With Losses of $100,000 to Contact the Firm - Business Wire
Protagonist Therapeutics director Waddill sells $217,000 in stock By Investing.com - Investing.com South Africa
Protagonist Therapeutics director Waddill sells $217,000 in stock - Investing.com
Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025? - MSN
These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company
Fast Company Ranks Protagonist Among Elite Biotech Innovators: 2 FDA Filings Coming - StockTitan
Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
Protagonist Therapeutics CFO Ali Asif sells $1.46 million in stock By Investing.com - Investing.com South Africa
Protagonist Therapeutics’ chief medical officer sells $1.7 million in stock By Investing.com - Investing.com Canada
Protagonist Therapeutics CFO Ali Asif sells $1.46 million in stock - Investing.com India
Protagonist Therapeutics’ chief medical officer sells $1.7 million in stock - Investing.com
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $76.00 - Defense World
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Victory Capital Management Inc. - Defense World
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out - MSN
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Bank of New York Mellon Corp - Defense World
Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com South Africa
Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why - Yahoo Finance
Learn to Evaluate (PTGX) using the Charts - Stock Traders Daily
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $72.00 at BMO Capital Markets - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Hits New 1-Year High on Analyst Upgrade - Defense World
Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It (NASDAQ:PTGX) - Seeking Alpha
Wedbush Adjusts Protagonist Therapeutics Price Target to $70 From $58, Maintains Outperform Rating - Marketscreener.com
Protagonist Therapeutics Soars as Icotrokinra Drives Breakthroug - GuruFocus.com
Protagonist Therapeutics price target raised to $76 from $60 at Truist - TipRanks
Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success - Yahoo Finance UK
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Protagonist Therapeutics price target raised to $72 from $62 at BMO Capital - TipRanks
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Shares Climb 44% But Its Business Is Yet to Catch Up - Simply Wall St
Protagonist Therapeutics price target raised to $80 from $54 at H.C. Wainwright - TipRanks
Protagonist Therapeutics Gets IBD Stock Rating Upgrade - Investor's Business Daily
10 Firms Buck Market Bloodbath on Monday - Insider Monkey
Protagonist Therapeutics’ (PTGX) Buy Rating Reaffirmed at HC Wainwright - Defense World
PTGX stock soars to 52-week high, reaching $50.18 By Investing.com - Investing.com Australia
BTIG maintains Buy on Protagonist Therapeutics, target at $73 By Investing.com - Investing.com Canada
Protagonist Therapeutics Inc Azioni (PTGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):